Literature DB >> 24163747

Recent advances in radiotherapy for thoracic tumours.

Michael Fay1, Christopher M Poole, Gary Pratt.   

Abstract

Radiation Oncology technology has continued to advance at a rapid rate and is bringing significant benefits to patients. This review outlines some of the advances in technology and radiotherapy treatment of thoracic cancers including brachytherapy, stereotactic radiotherapy, tomotherapy and intensity modulated radiotherapy. The importance of functional imaging with PET and management of movement are highlighted. Most of the discussion relates to non-small cell lung cancer but management of mesothelioma and small cell lung cancer are also covered. This technology has substantial benefits to patients in terms of decreasing toxicity both in the short and longer term.

Entities:  

Keywords:  Radiotherapy; advances; review; technology; thoracic

Year:  2013        PMID: 24163747      PMCID: PMC3804883          DOI: 10.3978/j.issn.2072-1439.2013.08.46

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  40 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Surgery versus stereotactic radiotherapy for patients with early-stage non-small cell lung cancer: more data from observational studies and growing clinical equipoise.

Authors:  Suresh Senan
Journal:  Cancer       Date:  2013-04-19       Impact factor: 6.860

3.  Thresholding in PET images of static and moving targets.

Authors:  Brian Yaremko; Terence Riauka; Don Robinson; Brad Murray; Abraham Alexander; Alexander McEwan; Wilson Roa
Journal:  Phys Med Biol       Date:  2005-12-06       Impact factor: 3.609

4.  Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.

Authors:  George R Blumenschein; Rebecca Paulus; Walter J Curran; Francisco Robert; Frank Fossella; Maria Werner-Wasik; Roy S Herbst; Philip O Doescher; Hak Choy; Ritsuko Komaki
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

5.  Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size.

Authors:  Naohisa Suzawa; Morihiro Ito; Shanlou Qiao; Katsunori Uchida; Motoshi Takao; Tomomi Yamada; Kan Takeda; Shuichi Murashima
Journal:  Lung Cancer       Date:  2010-09-29       Impact factor: 5.705

6.  Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation.

Authors:  Malcolm Feigen; Sze Ting Lee; Catherine Lawford; Katheryn Churcher; Eddy Zupan; Andrew M Scott; Chris Hamilton
Journal:  J Med Imaging Radiat Oncol       Date:  2011-06       Impact factor: 1.735

7.  Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer.

Authors:  Robert Timmerman; Lech Papiez; Ronald McGarry; Laura Likes; Colleen DesRosiers; Stephanie Frost; Mark Williams
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

8.  A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.

Authors:  Feng-Ming Spring Kong; Kirk A Frey; Leslie E Quint; Randall K Ten Haken; James A Hayman; Marc Kessler; Indrin J Chetty; Daniel Normolle; Avraham Eisbruch; Theodore S Lawrence
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

9.  Defining the radiation target on a daily basis.

Authors:  H J Dobbs
Journal:  Cancer Imaging       Date:  2006-04-25       Impact factor: 3.909

10.  Automated biological target volume delineation for radiotherapy treatment planning using FDG-PET/CT.

Authors:  Maximilian Niyazi; Sonja Landrock; Andreas Elsner; Farkhad Manapov; Marcus Hacker; Claus Belka; Ute Ganswindt
Journal:  Radiat Oncol       Date:  2013-07-12       Impact factor: 3.481

View more
  4 in total

1.  Lung cancer.

Authors:  Kwun M Fong
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 2.  Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy-opportunities and challenges.

Authors:  Bing Xia; Shirong Zhang; Shenglin Ma
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 3.  The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review.

Authors:  A Youroukou; I Gkiozos; Z Kalaitzi; I Tsalafoutas; K Papalla; A Charpidou; V Kouloulias
Journal:  Clin Transl Oncol       Date:  2017-03-02       Impact factor: 3.405

4.  The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.

Authors:  Roberto Gomez-Casal; Chitralekha Bhattacharya; Michael W Epperly; Per H Basse; Hong Wang; Xinhui Wang; David A Proia; Joel S Greenberger; Mark A Socinski; Vera Levina
Journal:  Cancers (Basel)       Date:  2015-05-22       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.